Results 191 to 200 of about 9,895 (222)

PHYSIOLOGICAL “CONSTANTS” FOR PBPK MODELS FOR PREGNANCY

Journal of Toxicology and Environmental Health, 1997
Physiologically based pharmacokinetic (PBPK) models for pregnancy are inherently more complex than conventional PBPK models due to the growth of the maternal and embryo/fetal tissues. Physiological parameters such as compartmental volumes or flow rates are relatively constant at any particular time during gestation when an acute experiment might be ...
J F, Young, W S, Branham, D M, Sheehan, M E, Baker, W D, Wosilait, R H, Luecke   +5 more
openaire   +2 more sources

QSARs for PBPK modelling of environmental contaminants

SAR and QSAR in Environmental Research, 2011
Physiologically-based pharmacokinetic (PBPK) models are increasingly finding use in risk assessment applications of data-rich compounds. However, it is a challenge to determine the chemical-specific parameters for these models, particularly in time- and resource-limiting situations.
T, Peyret, K, Krishnan
openaire   +2 more sources

Postnatal Growth Considerations for PBPK Modeling

Journal of Toxicology and Environmental Health, Part A, 2007
A physiologically based pharmacokinetic (PBPK) model and Windows-based program (called PostNatal) was developed that focuses on postnatal growth, from birth through adulthood, using appropriate growth curves for each species and gender. Postnatal growth algorithms relating organs/tissues weights with total body weight for male and female humans, dogs ...
Richard H, Luecke, Bruce A, Pearce, Walter D, Wosilait, William, Slikker, John F, Young   +4 more
openaire   +2 more sources

PBPK in Preterm and Term Neonates: A Review

Current Pharmaceutical Design, 2018
The neonatal population remains one of the populations in which appropriate dosing regimens are still lacking, resulting in a large off-label or unlicensed use. Clinical research in these small infants remains a challenge, which sparks the need for modeling and simulation as an additional tool for neonatal drug research.The use of physiologically based
Robin, Michelet, Jan Van, Bocxlaer, An, Vermeulen   +2 more
openaire   +2 more sources

PBPK and Toxicokinetic Modeling

2022
Presentation to OpenTox 2022 on Sept. 16, 2022 Science Inventory, CCTE products: https://cfpub.epa.gov/si/si_public_search_results.cfm?advSearch=true&showCriteria=2&keyword=CCTE&TIMSType=&TIMSSubTypeID=&epaNumber=&ombCat=Any&dateBeginPublishedPresented=07/01/2017&dateEndPublishedPresented=&dateBeginUpdated=& ...
openaire   +1 more source

Development of a PBPK Model for Monoclonal Antibodies and Simulation of Human and Mice PBPK of a Radiolabelled Monoclonal Antibody

Current Pharmaceutical Design, 2009
Physiology based pharmacokinetic (PBPK) modeling and simulation is a useful method for prediction of biodistribution of both macromolecules and small molecules. It can enhance our understanding of the underlying mechanisms of biodistribution and hence may help in rational design of macromolecules used as diagnostic and therapeutic agents.
Tomi, Heiskanen, Tomas, Heiskanen, Kalevi, Kairemo   +2 more
openaire   +2 more sources

Analysis of PBPK Models for Risk Characterization

Annals of the New York Academy of Sciences, 1999
Abstract: Adoption of a Bayesian framework for risk characterization permits the seamless integration of different kinds of information available in order to choose and parameterize risk models. It also becomes easy to disentangle uncertainty from variability, through hierarchical statistical modeling.
openaire   +3 more sources

PBPK modeling of irbesartan: incorporation of hepatic uptake

Biopharmaceutics & Drug Disposition, 2015
AbstractPhysiological based pharmacokinetic (PBPK) modeling is now commonly used in drug development to integrate human or animal physiological data in order to predict pharmacokinetic profiles. The aim of this work was to construct and refine a PBPK model of irbesartan taking into account its active uptake via OATP1B1/B3 in order to predict more ...
Helene, Chapy, Sylvie, Klieber, Priscilla, Brun, Sabine, Gerbal-Chaloin, Xavier, Boulenc, Olivier, Nicolas   +5 more
openaire   +2 more sources

A PBPK model for midazolam in four avian species

Journal of Veterinary Pharmacology and Therapeutics, 2009
A physiologically based pharmacokinetic (PBPK) model was developed for midazolam in the chicken and extended to three other species. Physiological parameters included organ weights obtained from 10 birds of each species and blood flows obtained from the literature. Partition coefficients for midazolam in tissues vs.
K A, Cortright, S E, Wetzlich, A L, Craigmill   +2 more
openaire   +2 more sources